Erasca (ERAS) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Erasca (ERAS) has outperformed Travere Therapeutics (TVTX) over the past year, gaining 536.2% versus a gain of 98.6%. Over five years, TVTX leads with a +112.4% price change compared with -13.1% for ERAS. Erasca is the larger company by market cap ($5.41 billion vs $4.91 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | TVTX |
|---|---|---|
| Share price | $15.46 | $52.04 |
| Market cap | $5.41B | $4.91B |
| 1-day change | +9.49% | -2.62% |
| YTD return | +315.59% | +36.19% |
| 1-year return | +536.21% | +98.63% |
| 5-year return | -13.15% | +112.41% |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-0.95 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | $-124.55M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $24.28 | $68.73 |
| 52-week low | $2.11 | $22.59 |
| Distance from 52-week high | -36.33% | -24.28% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.95% | +44.52% |
| Average volume | 4.37M | 1.59M |
| Shares outstanding | 349.76M | 94.26M |
| Employees | 103 | 497 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed TVTX by 437.6 percentage points over the past year.
- The two companies sit in different sectors: Erasca in Health Care and Travere Therapeutics in Healthcare.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Healthcare · Biotechnology · 497 employees
ERAS vs TVTX FAQ
Which is bigger, Erasca or Travere Therapeutics?
Erasca (ERAS) is larger, with a market capitalization of $5.41B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, ERAS or TVTX?
ERAS returned +536.21% over the past 12 months, compared with +98.63% for TVTX (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Travere Therapeutics in the same industry?
No. Erasca is in the Health Care sector, while Travere Therapeutics is in Healthcare.